ArticleAnnals of medicine2025
Efficacy evaluation of autologous muscle flap transposition or myocutaneous flap transplantation for postoperative chronic empyema with bronchopleural fistula.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Surgical strategy for closure of postoperative bronchopleural fistula: a narrative review.Journal of thoracic disease · 2026Review
- Surgical strategies for spontaneous pneumothorax: a narrative review.Journal of visualized surgery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic empyema with bronchopleural fistula (BPF) after pulmonary resection is difficult to treat. The aim of the study is to explore the efficacy of autologous muscle flap or myocutaneous flap on chronic empyema with BPF.
methodsRetrospective analysis of 10 patients with postoperative chronic empyema with BPF treated in our hospital, including 8 males and 2 females, with ages ranging from 20 to 83 years, yielding an average age of (51.00 ± 19.22) years. The treatment of all patients with chronic empyema follows a staged surgical model. The first stage of surgery involves debridement, partial rib resection, and fistula closure, while the second stage includes autologous muscle flap transposition or free myocutaneous flap transplantation to eliminate the abscess cavity. The primary objectives of the first-stage surgery include ensuring adequate drainage, controlling infection, and achieving fistula closure. In contrast, the key focus of the second-stage surgery is the complete filling of the abscess cavity with a sufficient volume of autologous tissue flap.
resultsThere were no perioperative deaths. The average follow-up was (19.88 ± 9.03) months. None of the 10 patients had recurrence of empyema and BPF. All autologous muscle flaps or myocutaneous flaps survived. Postoperative chest computed tomography (CT) or magnetic resonance imaging (MRI) showed that the abscess cavity disappeared.
conclusionsThe application of autologous muscle flap or myocutaneous flap represents an effective approach for the treatment of chronic empyema with BPF, demonstrating satisfactory clinical outcomes in the short to medium term.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.